Direct Injection of CAR-Engineered CD19.taNK Cells Demonstrating Potential “Vaccine” Protective Effect to be Highlighted ...
November 22 2016 - 8:17PM
Business Wire
NantKwest Inc. (Nasdaq:NK), a pioneering, next-generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases,
today announced that the Company’s abstract reviewing data on the
company’s CD19.taNK program has been accepted for an oral
presentation at the upcoming 58th Annual Meeting of the American
Society of Hematology (ASH) in San Diego, CA, December 3-6,
2016.
“NantKwest’s transition from preclinical to clinical studies
continues to make significant progress,” said Patrick Soon-Shiong,
MD, Chairman and CEO of NantKwest. “In these preclinical studies,
aNK cells expressing a CD19-CAR (CD19.taNK) demonstrated strong
killing of CD19-positive cancer cells. In addition, direct tumor
injections of CD19.taNK into a fully immunocompetent mouse model
induces tumor clearance and protection from tumor re-challenge,
suggesting the induction of a memory ('vaccine') protective effect
after the injection of the CD19.taNK cell.”
Presentation Summary
Intra-Tumor Injection of CAR-Engineered NK Cells Induces
Tumor Regression and Protection Against Tumor Re-Challenge
- Abstract #466,
https://ash.confex.com/ash/2016/webprogram/Paper95676.html
- Presenter: Laurent Boissel, PhD,
NantKwest, Woburn, MA
- Sunday, December 4, 2016, 5:15 PM, Room
5AB
This poster will review the potential use of CD19.taNK cells to
effectively kill cancer cells. In vivo preclinical studies of
direct tumor injection of CD19.taNK cells induces significant tumor
regression and significantly improved survival, with 75% of the
mice showing complete tumor regression at day 32 (p<0.05). Upon
re-challenge with A20 lymphoma cells, >80% mice remained free of
tumor after 14 days.
NantKwest
NantKwest (Nasdaq:NK) is a pioneering, next-generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact; (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody; and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies, including the reduction of risk of serious
"cytokine storms" reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest's NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest's NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care. For more information, please visit
http://www.nantkwest.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161122006204/en/
NantKwest Inc.Jen Hodson, 562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Mar 2024 to Apr 2024
NantKwest (NASDAQ:NK)
Historical Stock Chart
From Apr 2023 to Apr 2024